Science and Technology Park at Johns Hopkins

Center for Epigenetics

Science + Technology Park at Johns Hopkins provides over a million square feet of office and state-of-the-art facilities including chemistry and biology labs and GMP and NMR facilities.

The Center for Epigenetics has brought together investigators in genetics, biochemistry, cell biology, biostatistics, epidemiology, and clinical medicine to develop new technologies to apply to both basic science and population-based epigenetic studies. The center has developed several new genomics, biostatistical, and biochemical methods and is applying them to cutting-edge studies of epigenetic mechanisms and disease research.

The Johns Hopkins School of Medicine’s Brain Science Institute (BSi) brings together both basic and clinical neuroscientists from across the Johns Hopkins campuses. The BSi represents one of the largest and most diverse groups in the University.

Elixirgen is a biotechnology company focused on curing humanity’s ailments through stem cell biology. Founded in 2012 by Dr. Minoru Ko, a renowned specialist in molecular and cell biology, the company concentrates on regenerative and rejuvenative medicine, and deals with research in both basic science and in the application of the technologies it discovers and refines.

Elixirgen is located in the Science + Technology Park at Johns Hopkins in Baltimore, an ideal research environment that allows Elixirgen’s scientists to conduct research at state-of-the-art facilities.

Elixirgen Scientific

A clinical-stage biotechnology company focused on the discovery, development, and commercialization of therapies for genetic diseases and vaccines.

Elixirgen Therapeutics, LLC

A company dedicated to integrating early cancer screening into routine medical care, helping to provide navigation for the care process

Exact Sciences Thrive LLC

At the IBBS in the Johns Hopkins School of Medicine, we work at the boundaries of current knowledge in biology, laying the foundations of future advances in prevention, diagnosis and treatment.

Any type of research is possible in the IBBS -- in addition to our nine departments, we have several interdisciplinary research programs as well as translational and collaborative research across all basic and clinical departments.

Institute for Basic Biomedical Sciences

www.hopkinsmedicine.org/institute_basic_biomedical_sciences

TRANSFORMING ACADEMIC TRANSLATIONAL RESEARCH AT JOHNS HOPKINS

Since 2009, the Johns Hopkins Drug Discovery program has provided the Johns Hopkins community with core expertise in drug discovery research including medicinal chemistry, screening assay development, drug metabolism and pharmacokinetics, and animal pharmacology/toxicology. The Johns Hopkins Drug Discovery Program, located in Baltimore, MD, works with the researchers across Johns Hopkins to research and develop tomorrow’s therapeutics for a wide range of human disorders.

855 N. Wolfe Street, Rangos Building Suite 279

Johns Hopkins Drug Discovery

FastForward is an accelerator at Johns Hopkins that serves as a catalyst for the advancement and commercialization of an array of innovations that are derived both at the University and elsewhere. The goal of FastForward is to help early ventures increase the probability of realizing their potential and bring innovation and life-changing technologies to market.

Johns Hopkins FastForward

The Johns Hopkins Health System Corporation and Johns Hopkins Medicine Legal Department The mission and purpose of The Johns Hopkins Health System Legal Department are to ensure that the Health System operates in accordance with applicable laws and regulations and to support the mission, vision and values of the Health System. The Legal Department provides high quality legal and strategic advice in support of our clients’ goals and strategic priorities. We serve our clients with an uncompromising commitment to service excellence and responsiveness.

Johns Hopkins Medical Legal Department

www.hopkinsmedicine.org/administrative/legal_jhm.html

Johns Hopkins Technology Ventures helps develop new discoveries and inventions into products and services that benefit society and transform the world. We help inventors and entrepreneurs protect and license their innovations and foster collaboration with business partners who specialize in launching new inventions.

Our mission is to protect the intellectual property of Johns Hopkins faculty and to commercialize these inventions for the public good and bring the benefits of discovery to the world.

Johns Hopkins Technology Ventures

A clinical stage pharmaceutical company committed to extending healthy lifespan through developing novel immunotherapies focused on aging disorders and autoimmune diseases.

MyMD Pharmaceuticals™

The JHU Center for Polycystic Kidney Disease is comprised of a group of world renowned and NIH-funded research laboratories with both physician and basic scientists. Center members are using an interdisciplinary, state-of-the-art approach to understand the pathogenetic mechanisms underlying various forms of human polycystic kidney disease (PKD).

PKD consists of a diverse group of hereditary disorders affecting approximately 600,000 persons in the United States alone. It is one of the most common inherited diseases in humans and the fourth leading cause of end stage kidney disease worldwide. The disorder results in the formation of fluid-filled renal cysts rendering the destruction of normal renal structure and function. There are currently no cures for the disease. The center’s efforts are directed at developing curative therapies for PKD through an understanding of basic renal biology in health and disease.

PKD Core Center

www.hopkinsmedicine.org/Nephrology/pkd.html

The Division of Infectious Diseases has laboratories focused on understanding the pathogenesis and transmission of infections of global significance.

The Viral Hepatitis Center combines the work of 5 NIH-funded Principal Investigators focused on translating clinical observation to basic principles. Starting from well-characterized cohorts of volunteers who have hepatitis B or hepatitis C virus infection, we investigate clinical phenotypes, epidemiologic variables, human and viral genomic variation, cellular and humoral adaptive immunity, and innate immunity. There is a special interest in the impact of HIV on these infections. The goal of this team is to develop better methods to prevent and treat chronic viral hepatitis, and synthesize our findings to understand the basic mechanisms governing human immune responses to acute and chronic viral infections.

Center for Epigenetics

.css-1bhuh3n-StoreDetailsView{display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-box-pack:justify;-webkit-justify-content:space-between;justify-content:space-between;gap:2rem;}Center for Epigenetics

More stores you might like

Center for Epigenetics